Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | NSD2 | O96028 | 1/20 | 0.64 |
| ▸ | ALPL | P05186 | 1/20 | 0.64 |
| ▸ | ALPI | P09923 | 1/20 | 0.64 |
| ▸ | ALPG | P10696 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.61 |
| ▸ | TOP1 | P11387 | 3/20 | 0.59 |
| ▸ | TOP2A | P11388 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28235986 | 0.82 | KDM4E (0.67) | KDM4ELMNATDP1ALDH1A1MAPT | |
| SCHEMBL11797156 | 0.81 | HDAC6 (0.58) | KDM4EHDAC6CA12CA1CA9 | |
| SCHEMBL1304499 | 0.78 | KDM4E (1.00) | KDM4ELMNATDP1ALDH1A1MAPT | |
| SCHEMBL469871 | 0.78 | KDM4E (0.61) | KDM4ELMNATDP1ALDH1A1MAPT | |
| SCHEMBL10530665 | 0.77 | HDAC1 (0.63) | KDM4ETDP1POLBHDAC6CA12 | |
| SCHEMBL18346609 | 0.76 | HDAC6 (1.00) | KDM4EMAPTPOLBGAAL3MBTL1 | |
| SCHEMBL13064962 | 0.76 | TOP1 (0.80) | KDM4ELMNATDP1ALDH1A1MAPT | |
| SCHEMBL13286830 | 0.76 | KDM4E (0.65) | KDM4ELMNATDP1ALDH1A1MAPT | |
| SCHEMBL171446 | 0.76 | HDAC6 (1.00) | KDM4EMAPTPOLBGAAL3MBTL1 | |
| SCHEMBL7045449 | 0.75 | KDM4E (0.57) | KDM4ELMNATDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017353-B1 | THERAPEUTIC PROCESS FOR INHIBITING NF-KAPPA B | ELFORD HOWARD L (US) | 2012-03-07 | — | — | EP | claimed |
| US-6924308-B1 | Therapeutic process for inhibiting NF-κB | MOLECULES FOR HEALTH, INC. | 2005-08-02 | — | — | US | claimed |
| US-4394389-A | ANTITUMOR AGENTS | RIET BARTHOLOMEUS VAN T | 1983-07-19 | — | — | US | claimed |
| US-20240155902-A1 | DISPLAY PANEL AND DISPLAY DEVICE | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-117292643-A | Display panel and display device | 武汉天马微电子有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| US-8932617-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140303064-A1 | WASHING AND CLEANING COMPOSITIONS WITH IMPROVED PERFORMANCE | HENKEL AG & CO. KGAA (DE) | 2014-10-09 | — | — | US | disclosed |
| EP-1017353-B1 | THERAPEUTIC PROCESS FOR INHIBITING NF-KAPPA B | ELFORD HOWARD L (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-6030942-A | TO TREAT CANCER AND VIRAL AND BACTERIAL INFECTIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-02-29 | — | — | US | disclosed |
| US-5366996-A | Administering hydroxamic acids | ELFORD HOWARD L (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0140958-B1 | ONCOLYTIC DRUG COMBINATIONS | ELFORD, Howard L. (US) | 1989-12-20 | — | — | EP | disclosed |
| EP-0140958-A4 | ONCOLYTIC DRUG COMBINATIONS. | ELFORD HOWARD L (US) | 1985-09-02 | — | — | EP | disclosed |
| EP-0140958-A1 | ONCOLYTIC DRUG COMBINATIONS. | ELFORD HOWARD L (US) | 1985-05-15 | — | — | EP | disclosed |
| WO-1984004246-A1 | ONCOLYTIC DRUG COMBINATIONS | ELFORD HOWARD L | 1984-11-08 | — | — | WO | disclosed |
| US-4448730-A | ANTITUMOR AGENTS | RIET BARTHOLOMEUS VAN T | 1984-05-15 | — | — | US | disclosed |
| US-4394389-A | ANTITUMOR AGENTS | RIET BARTHOLOMEUS VAN T | 1983-07-19 | — | — | US | disclosed |
| US-4263322-A | RIBONUCLEOTIDE REDUCTASE INHIBITORS | RIET BARTHOLOMEUS VAN T | 1981-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | KDM4E 3319/4885LMNA 2888/4885TDP1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.